Incyte Genomics Announces the Opening of Its Japanese Subsidiary Palo Alto, CA, and Tokyo, Japan, October 15, 2001 - Incyte Genomics, Inc (Nasdaq: INCY), the leading genomics information company, announced today the official opening of its office in Tokyo, Japan will take place on October 16, 2001. Incyte provides genomics technologies and products that support pharmaceutical companies and biotechnology firms and academic institutions in their search for better and faster prevention, diagnosis and treatment of disease. The company has developed an international network of collaborators, including several key Japanese pharmaceutical companies. "We are excited to be establishing an office in Japan and to participate directly in one of the most active pharmaceutical research markets in the world," said Roy A. Whitfield, Chief Executive Officer of Incyte. "Sankyo, Sumitomo and Eisai are among the pharmaceutical companies already using our LifeSeq Gold database to further their internal research efforts. And we hope to expand that impressive list." Contact information for Incyte's Japanese office: Incyte Genomics Asia, Inc. Japan Branch 1-26-2 Nishi-Shinjuku (Level 32) Shinjuku-ku, Tokyo 163-0532 Japan Phone: 81 (3) 5322-2871 Fax: 81 (3) 5322-2875 Incyte Genomics LifeSeq® Gold database provides researchers with a comprehensive view of the entire human genome by integrating proprietary expressed sequence tag (EST) and full-length gene sequence information and mapping data, in addition to public genomic sequence information. The database contains more than 120,000 gene transcripts of which approximately half are not commercially available elsewhere. Incyte Genomics, Inc. has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. In addition, Incyte has the largest portfolio of issued United States patents covering human full-length genes and the proteins they encode and is leveraging its intellectual property position to be a leader in therapeutic discoveries. For more information, visit Incyte's web site at http://www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, including statements as to the ability of these business decisions to advance the company's financial performance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the impact of genomic information in advancing medical research; the impact of technological and scientific advances; the impact of competition and the ability of the collaboration to compete with researchers or research teams that may have greater financial or other resources; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2001. These forward-looking statements speak only as of the date hereof. Incyte disclaims any intent or obligation to update these forward-looking statements.